Water-soluble Parkinson's treatment shows promise

Scientists from Zymes, the University of Windsor in Ontario, Canada, and the National Research Council of Canada have presented research on a potential treatment for halting the progression of Parkinson's disease using Zymes' water soluble CoQ10 formulation.

Studies have shown that mitochondrial dysfunction/oxidative stress is a major contributor to Parkinson's disease, a neurodegenerative disorder resulting from the progressive loss of select neurons in the brain. However, in an animal model, the CoQ10 provided significant protection of dopaminergic neurons and a decrease in symptoms. The animals were given CoQ10 in their drinking water with access 24 hours a day both before and after treatment, according to Zymes statement.

Because the animals were exposed regularly to the CoQ10 in their water, scientists hypothesize that small doses given several times a day is a more effective method of administration than larger doses administered once or twice daily.

Dr. Shelley Weinstock, Zymes senior VP of research and scientific affairs, says the company is very excited about the early stage findings; however, more research will be needed to determine if the treatment will be effective in halting the progression of Parkinson's disease in people.

- here's the Zymes release

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.